Rheumatology Medical News about Alendronate, Glucocorticoid, Osteoporosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial
Journal of Rheumatology, 08/13/09

Stoch SA et al. – Study reports that over 12 months, alendronate 70 mg once weekly (ALN OW) significantly increased lumbar spine, trochanter, total hip, and total body BMD compared with baseline among patients taking glucocorticoid therapy.

Methods

An evaluation of the efficacy and safety of ALN OW for prevention and treatment of bone loss in pts on glucocorticoid therapy
12-mo trial with 114 and 59 pts in the treatment and placebo arms, respectively
Participants were stratified according to the duration of prior oral glucocorticoid therapy at randomization
Participants received alendronate 70 mg once weekly (ALN OW) or placebo
All received supplemental daily calcium (1000 mg) and 400 IU vit D
Clinical evaluations were performed at baseline, 3, 6, 9, and 12 mo

Results

At 12 mo, there was a mean percentage increase from baseline in the ALN OW group for:
- Lumbar spine (2.45%)
- Trochanter (1.27%)
- Total hip (0.75%), and
- Total body (1.70%) bone mineral density (BMD)
At 12 mo significant treatment difference for the mean % change from baseline was observed for lumbar spine, trochanter and total hip
Biochemical markers of bone remodeling also showed a mean % decreases from baseline

<< Previous
Changes in lipid profile between flare and remission of patients...

Next >>
Prevalence and risk factors for pulmonary arterial hypertension...